ArticleFrontiers in pharmacology2026
Disitamab vedotin plus toripalimab as a first-line treatment for HER2-expressing advanced urothelial cancer: a cost-effectiveness analysis from China based on the RC48-C016 trial.
Xiaolin Yun et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.